E-cigarettes increase risk of chronic lung disease
Article written by Peter Mas-Mollinedo E-cigarette use significantly increases a person’s risk of developing chronic lung diseases..
Article written by Peter Mas-Mollinedo E-cigarette use significantly increases a person’s risk of developing chronic lung diseases..
Merck Inc., announced that the FDA has accepted for priority review the New Drug Application (NDA) for BAY 1021189 (vericiguat), an orally administered soluble guanylate cyclase (sGC) stimulator,… read more.
Boehringer and Eli Lilly announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance (empagliflozin) in adults with chronic heart… read more.
Teleflex Incorporated announced the first patient enrollment in a clinical study that will evaluate the performance of Teleflex coronary guidewires and specialty catheters in Chronic Total Occlusion (CTO)… read more.
Esperion announced that the European Commission approved the Nilemdo (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine. Nilemdo is a first-in-class ATP Citrate Lyase (ACL)… read more.
Esperion announced the European Commission approved the Nustendi (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine for hypercholesterolemia and dyslipidemia in Europe. Nustendi… read more.
Xarelto ( rivaroxaban) reduced the risk of major venous thromboembolism (VTE) by about 75% in adult patients during a period of immobilization after nonmajor lower limb orthopaedic surgery,… read more.
Regeneron Pharmaceuticals announced that detailed Phase III ELIPSE HoFH trial results of REGN 1500 (evinacumab) in patients with homozygous familial hypercholesterolemia (HoFH). The data showed the trial met… read more.
Regeneron Pharma has presented Phase III ODYSSEY HoFH trial results from a late-breaking presentation, demonstrating the effect of Praluent (alirocumab) in patients with homozygous familial hypercholesterolemia (HoFH). The… read more.
Merck Inc announced the presentation of results from the VICTORIA trial, a Phase III study evaluating the efficacy and safety of its investigational drug BAY 1021189 (vericiguat), an… read more.
Written by Bruce Sylvester Researchers report that there is no link between statin use and cognitive decline. The findings were published on Nov. 18, 2019 in the Journal… read more.
A new study from St. Michael’s Hospital in Toronto, Canada shed lights on how a class of medications that help regulate blood sugar for patients with Type 2… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.